Dual GIP/GLP-1 agonists, such as tirzepatide, show greater reductions in weight and blood sugar than GLP-1-only medications
Theyre sometimes both prescribed to provide improved blood sugar control
Laudenslager, who was not involved in the study, points out that it was observational in nature, meaning it looked at correlation not causation
I lean towards the 10% weight loss being the primary driver, but as I said, GLP-1 seems to have these off target effects that seem to be positive
The EP-1 (S) & Cagrilintide blend is supplied strictly for laboratory research use only
As it aids in breaking down these molecules, it can provide a boost to metabolic rates, offering support to those keen on weight management and reduction